Conjugates for treating diseases caused by PSMA expressing cells
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
1. A method of treating prostate cancer in a patient, comprising administering a therapeutically effective amount of a conjugate having a formula
or a pharmaceutically acceptable salt thereof.
2. A method of treating prostate cancer in a patient, comprising administering a composition comprising a therapeutically effective amount of a conjugate having a formula
or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the patient is a human.
4. The method of claim 2 , wherein the composition is administered to the patient in an oral dosage form.
5. The method of claim 4 , wherein the oral dosage form is selected from the group consisting of a tablet, a capsule, an elixir, and a syrup.
6. The method of claim 2 , wherein the composition is administered to the patient in a parenteral dosage form.
7. The method of claim 6 , wherein the parenteral dosage form is administered to the patient through a route selected from the group consisting of intravenous, intraarterial, intraperitoneal, epidurial, intraurethral, intrasternal, intramuscular, and subcutaneous.
8. The method of claim 2 , wherein the therapeutically effective amount is from about 1 μg/kg to about 1 g/kg.
9. The method of claim 2 , wherein the therapeutically effective amount is administered in a single dosage.
10. The method of claim 2 , wherein the therapeutically effective amount is administered in a divided dosage.
11. The method of claim 2 , wherein the therapeutically effective amount is administered once daily.
12. The method of claim 2 , wherein the therapeutically effective amount is administered twice daily.
13. The method of claim 2 , wherein the therapeutically effective amount is administered thrice daily.
14. The method of claim 2 , wherein the therapeutically effective amount is administered once a week.
15. The method of claim 2 , wherein the therapeutically effective amount is administered once a month.
16. The method of claim 2 , wherein the therapeutically effective amount is administered once a quarter.
17. The method of claim 2 , wherein the composition further comprises a pharmaceutically-acceptable carrier, a pharmaceutically-acceptable adjuvant, a pharmaceutically-acceptable vehicle, a pharmaceutically-acceptable excipient, or a combination thereof.
18. The method of claim 2 , wherein the composition is in a form selected from the group consisting of a tablet, a pill, a powder, a lozenge, a sachet, a cachet, an elixir, a suspension, an emulsion, a solution, a syrup, a solid aerosol, an aerosol in a liquid medium, an ointment, a soft gelatin capsule, a hard gelatin capsule, and a suppository.
19. The method of claim 18 , wherein the composition is in a form selected from the group consisting of a sterile injectable solution and a sterile packaged powder.